In-vitro studies have shown that high doses of selenium have powerful anti-cancer properties. But until recently, scientists have been unable to test this treatment in humans, as excessive amounts of selenium are toxic. Now a study in Redox Biology shows a promising workaround — selenium nanoparticles. Study Details Using modelsRead
The following are studies with full text downloads that focus on genetic variants and how they affect serum concentrations of important nutrients, such as lycopene, selenium and others. A Common Variant in the SETD7 Gene Predicts Serum Lycopene Concentrations By Christopher R. D’Adamo, et al published in J. Nutrients, Feb.Read
It’s been twenty-one years since the first study reported a possible link between elevated serum selenium and prostate cancer risk reduction. In the years since, research has continued to explore this mineral’s role in cancer risk reduction. A literature review in the journal Medicine released this week continues the steadyRead
For the first time ever, researchers have made a significant positive connection between biomarkers of oxidative sress, a standardized form of selenium-enriched yeast and reduced prostate cancer risk. Results from long-term clinical trial suggest that selenium-enriched yeast (SY), in a dose-dependent, standardized form from SelenoExcell, but not selenomethionine (SeMet) may be effective at reducing prostate cancer risk. This study confirmed reductions in biomarkers of oxidative stress following supplementation with the standardized form of SY but not SeMet in healthy men. By John P Richie Jr PhD, Karam el-Bayoumy PhD et al, published in Cancer Prevention Research, August 2014.